Wuhan Hiteck Biological Pharma Co Ltd (300683) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.008x

Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has a cash flow conversion efficiency ratio of -0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-17.49 Million ≈ $-2.56 Million USD) by net assets (CN¥2.24 Billion ≈ $328.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Wuhan Hiteck Biological Pharma Co Ltd to measure how many days the company can operate on defensive assets alone.

Wuhan Hiteck Biological Pharma Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Wuhan Hiteck Biological Pharma Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shenzhen Jinxinnong Feed Co Ltd SHE:002548	-0.071x
Tongqinglou Dining Co Ltd SHG:605108	N/A
Zhejiang East Crystal Electronic Co Ltd SHE:002199	0.016x
Healthcare Co Ltd SHG:603313	0.109x
Hubei Fuxing Science and Technology Co Ltd SHE:000926	-0.077x
Longmaster Information Tech SHE:300288	-0.007x
Universal Cables Limited NSE:UNIVCABLES	-0.002x
ROPEOK Technology Group Co Ltd SHG:688619	0.004x

Annual Cash Flow Conversion Efficiency for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see 300683 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥2.41 Billion ≈ $352.89 Million	CN¥22.69 Million ≈ $3.32 Million	0.009x	+341.74%
2023-12-31	CN¥2.50 Billion ≈ $365.17 Million	CN¥5.31 Million ≈ $777.64K	0.002x	-90.62%
2022-12-31	CN¥2.34 Billion ≈ $341.71 Million	CN¥53.03 Million ≈ $7.76 Million	0.023x	+340.20%
2021-12-31	CN¥2.34 Billion ≈ $342.86 Million	CN¥12.09 Million ≈ $1.77 Million	0.005x	+145.17%
2020-12-31	CN¥1.72 Billion ≈ $252.41 Million	CN¥-19.70 Million ≈ $-2.88 Million	-0.011x	-131.90%
2019-12-31	CN¥1.76 Billion ≈ $257.61 Million	CN¥63.03 Million ≈ $9.22 Million	0.036x	-16.64%
2018-12-31	CN¥1.71 Billion ≈ $250.17 Million	CN¥73.42 Million ≈ $10.74 Million	0.043x	-15.06%
2017-12-31	CN¥1.64 Billion ≈ $240.44 Million	CN¥83.08 Million ≈ $12.16 Million	0.051x	-75.28%
2016-12-31	CN¥703.35 Million ≈ $102.92 Million	CN¥143.86 Million ≈ $21.05 Million	0.205x	-23.66%
2015-12-31	CN¥596.76 Million ≈ $87.32 Million	CN¥159.89 Million ≈ $23.40 Million	0.268x	+6.18%
2014-12-31	CN¥536.59 Million ≈ $78.52 Million	CN¥135.40 Million ≈ $19.81 Million	0.252x	-16.35%
2013-12-31	CN¥254.64 Million ≈ $37.26 Million	CN¥76.82 Million ≈ $11.24 Million	0.302x	--

About Wuhan Hiteck Biological Pharma Co Ltd

SHE:300683 China Drug Manufacturers - Specialty & Generic

Market Cap

$463.91 Million

CN¥3.17 Billion CNY

Market Cap Rank

#12806 Global

#3799 in China

Share Price

CN¥24.22

Change (1 day)

+0.17%

52-Week Range

CN¥24.18 - CN¥59.56

All Time High

CN¥84.19